LL-37 and the Intestinal Barrier: Gut Defense

LL-37 in the Gut

Dual barrier effects

LL-37 both protects and transiently disrupts the intestinal epithelial barrier depending on concentration and context, with low doses enhancing tight junctions and high doses temporarily increasing permeability.

Otte et al., Regulatory Peptides, 2009

Otte et al., Regulatory Peptides, 2009

View as image

The intestinal epithelium is a single cell layer separating the body's interior from the microbial world of the gut lumen. This barrier must accomplish two conflicting tasks: absorb nutrients while blocking bacteria, toxins, and undigested proteins. LL-37, the human cathelicidin, is produced by intestinal epithelial cells as part of the barrier defense system. But its relationship with the barrier is more complex than simple protection. As the pillar article on LL-37 in the gut describes, this peptide has multiple roles in intestinal homeostasis. This article focuses specifically on how LL-37 interacts with the physical barrier itself: tight junctions, mucus, and epithelial integrity.

LL-37 Expression Along the GI Tract

LL-37 is not limited to airway epithelium. The cathelicidin peptide is expressed by epithelial cells throughout the gastrointestinal tract. Hase et al. (2003) demonstrated that human gastric epithelial cells produce LL-37, particularly in areas of Helicobacter pylori infection^[3]. In the stomach, LL-37 provides a first-line defense against ingested pathogens that survive gastric acid.

In the colon, LL-37 expression is constitutive but modulated by the local microbial environment. Schauber et al. (2003) showed that short-chain fatty acids, particularly butyrate, upregulate cathelicidin expression in colonic epithelial cells^[2]. Butyrate is produced by fermentation of dietary fiber by commensal gut bacteria, primarily Clostridia species. This creates a feedback loop: dietary fiber feeds butyrate-producing bacteria, which increase LL-37 production, which kills pathogenic bacteria while sparing commensals. The fiber-butyrate-cathelicidin axis links diet directly to intestinal antimicrobial defense.

Iimura et al. (2005) demonstrated that cathelicidin mediates innate intestinal defense against colonization with enteropathogenic bacteria^[5]. Mice deficient in cathelicidin (CRAMP, the mouse ortholog of LL-37) showed increased susceptibility to intestinal infection, with higher bacterial loads and more severe mucosal damage. Restoring cathelicidin expression rescued barrier function and reduced bacterial colonization.

The Tight Junction Paradox

The most interesting finding in LL-37 gut research is its context-dependent effect on epithelial permeability. Otte et al. (2009) studied LL-37's effects on intestinal epithelial barrier integrity using Caco-2 and HT-29 cell monolayers^[1].

In healthy, uninfected cells: LL-37 caused a rapid, transient increase in epithelial permeability. Transepithelial electrical resistance (TEER, a measure of barrier tightness) decreased within hours of LL-37 exposure. This permeability increase was associated with endocytosis and lysosomal degradation of the tight junction proteins occludin and claudin-2.

In infected cells: When epithelial cells were infected with Salmonella typhimurium (which disrupts tight junctions as part of its invasion strategy), LL-37 restored barrier integrity. The peptide reorganized ZO-1, a scaffolding protein that anchors tight junctions to the cytoskeleton, and improved epithelial resistance.

This dual behavior makes biological sense. In the context of active infection, barrier restoration prevents bacterial translocation into the bloodstream. The transient permeability increase in healthy tissue may serve a different purpose: allowing immune cells and immune mediators to cross the epithelium more easily, enhancing immune surveillance. The temporary opening of tight junctions by LL-37 could facilitate recruitment of neutrophils and macrophages to sites where the peptide has detected bacterial breach.

Fabisiak et al. (2016) reviewed the pleiotropic activities of LL-37 and noted that the peptide's effect on any given tissue depends on concentration, timing, and the inflammatory state of the tissue^[6]. This context-dependency is a recurring theme in cathelicidin biology: the same peptide can promote healing, enhance immunity, or cause tissue damage depending on the local conditions.

Mucus Layer Enhancement

Beyond tight junctions, LL-37 strengthens the mucus layer that coats the intestinal epithelium. The mucus layer is the first physical barrier separating luminal bacteria from epithelial cells. It is composed primarily of mucin glycoproteins (MUC2 in the colon) secreted by goblet cells.

Research has demonstrated that LL-37 enhances expression of MUC1, MUC2, and MUC3 in colonic epithelial cells. MUC2 is the structural backbone of the colonic mucus gel. MUC1 and MUC3 are transmembrane mucins that form a glycocalyx on the epithelial cell surface, providing additional protection. By increasing all three mucins, LL-37 strengthens both the secreted mucus layer and the cell-surface glycocalyx.

This mucin-inducing effect provides a barrier-protective mechanism independent of direct bacterial killing. Even if LL-37 concentrations are too low to kill bacteria directly, enhanced mucus production physically separates bacteria from the epithelial surface, reducing the likelihood of invasion and the inflammatory signaling that follows bacterial-epithelial contact.

The colon has two distinct mucus layers. The outer layer is loose and colonized by commensal bacteria. The inner layer is dense, sterile, and directly attached to the epithelium. Breakdown of the inner mucus layer is one of the earliest events in ulcerative colitis pathogenesis, allowing bacteria to contact the epithelial surface and trigger inflammation. LL-37's ability to enhance MUC2 production (the primary structural mucin of the inner layer) positions it as a potential protective factor against this breakdown. Whether endogenous LL-37 levels are sufficient to maintain the inner mucus layer, or whether therapeutic supplementation would be needed to achieve this effect, is unknown.

The relationship between LL-37 and goblet cells (the specialized cells that produce and secrete mucins) is also relevant. LL-37 may promote goblet cell differentiation from stem cell progenitors in the intestinal crypt, potentially increasing the total mucus-producing capacity of the epithelium. This would represent a longer-term structural defense enhancement beyond the immediate antimicrobial killing that LL-37 provides.

LL-37 in Inflammatory Bowel Disease

Sun et al. (2016) reviewed the roles of cathelicidin LL-37 in inflammatory bowel disease (IBD)^[4]. The relationship is complex and not fully resolved.

In Crohn's disease, reduced cathelicidin expression in ileal mucosa has been reported. This deficiency may contribute to the impaired antimicrobial defense seen in Crohn's patients, who often have adherent-invasive E. coli colonizing their ileal mucosa. Reduced LL-37 means reduced bacterial killing at the mucosal surface.

In ulcerative colitis, the picture is different. Some studies report increased LL-37 expression in inflamed colonic tissue, possibly reflecting an attempt by the epithelium to defend against bacterial invasion during active inflammation. The elevated LL-37 may contribute to the inflammatory process itself, given the peptide's ability to activate immune cells and enhance cytokine production at high concentrations.

Wu et al. (2010) reviewed cathelicidins in inflammation and tissue repair and proposed that cathelicidin serves a dual role in the gut: antimicrobial defense during the acute phase and wound healing during the resolution phase^[7]. LL-37 promotes epithelial cell migration and proliferation, which are essential for repairing mucosal ulcers. This wound-healing function is distinct from the antimicrobial function and contributes to barrier restoration after injury.

The IBD data highlights a fundamental question: is LL-37 deficiency a cause of intestinal barrier dysfunction in IBD, or is it a consequence of the disease process? Both directions of causation are supported by evidence, and the relationship is likely bidirectional. Mucosal inflammation reduces healthy epithelial cell numbers (which produce LL-37), and reduced LL-37 allows more bacterial invasion (which worsens inflammation). Breaking this cycle is a potential therapeutic strategy: exogenous LL-37 or LL-37-inducing agents (like butyrate or vitamin D) could theoretically restore antimicrobial defense in IBD patients with cathelicidin deficiency.

Animal models support this approach. Cathelicidin-deficient mice develop more severe experimental colitis than wild-type mice, and administration of exogenous cathelicidin reduces colitis severity. In polymicrobial sepsis models, cathelicidin preserves intestinal barrier function by reducing bacterial translocation and modulating neutrophil and macrophage infiltration into the gut wall. These preclinical findings suggest that restoring cathelicidin levels in IBD could break the inflammation-barrier dysfunction cycle, but no human clinical trial has tested LL-37 supplementation for IBD.

Connection to Diet and the Microbiome

The butyrate regulation of LL-37 expression creates a direct link between dietary fiber intake and intestinal barrier defense. Diets low in fiber produce less butyrate, which reduces colonic cathelicidin expression, which weakens antimicrobial defense, which may increase susceptibility to pathogenic colonization and barrier disruption.

This pathway may explain part of the well-documented association between low-fiber Western diets and increased rates of IBD, colorectal infection, and barrier-related diseases. The mechanism is not speculative: each link in the chain (fiber to butyrate, butyrate to cathelicidin, cathelicidin to bacterial killing and barrier function) has direct experimental support.

The practical implication is that dietary fiber may be an indirect way to boost intestinal LL-37 production. Fermentable fibers (inulin, resistant starch, beta-glucan) that specifically feed butyrate-producing bacteria would be the most effective. This connects cathelicidin biology to the broader field of prebiotics and microbiome-targeted nutrition. The therapeutic potential of butyrate supplementation (either as oral butyrate or as encapsulated butyrate delivered to the colon) for enhancing cathelicidin expression in IBD patients has been proposed but not tested in randomized controlled trials.

Vitamin D provides a second dietary lever for LL-37 expression. While the vitamin D-cathelicidin axis is best characterized in skin and airway epithelium, vitamin D receptors are also expressed in intestinal epithelial cells. Vitamin D supplementation could theoretically increase both systemic and intestinal LL-37 production simultaneously, addressing barrier defense from multiple angles. The combination of adequate vitamin D status and sufficient dietary fiber may represent a two-pronged approach to optimizing endogenous cathelicidin production throughout the GI tract.

The interaction between LL-37 and the commensal gut microbiome adds another layer. LL-37 has selective antimicrobial activity that preferentially kills Gram-negative pathogens over Gram-positive commensals at physiological concentrations. This selectivity helps maintain a healthy microbial balance while defending against invaders. How the microbiome in turn regulates LL-37 expression (through metabolites like butyrate) creates a homeostatic loop that, when functioning, maintains both microbial balance and barrier integrity.

For comparison with other gut-protective peptides, BPC-157 and KPV operate through different mechanisms. BPC-157 may enhance angiogenesis and growth factor expression in the gut wall. KPV blocks NF-kB to reduce inflammatory signaling. LL-37 works at the barrier interface itself, combining direct antimicrobial killing, tight junction modulation, mucus enhancement, and epithelial wound healing.

The Bottom Line

LL-37 plays a multifaceted role in intestinal barrier defense. It is expressed throughout the GI tract, with colonic expression regulated by butyrate from commensal bacteria. LL-37's effects on tight junctions are context-dependent: it restores barrier integrity in infected epithelium but can transiently increase permeability in healthy cells. It enhances mucin expression (MUC1, MUC2, MUC3), strengthening the mucus layer. In IBD, cathelicidin expression is altered in disease-specific patterns, with deficiency in Crohn's disease and elevation in ulcerative colitis. The fiber-butyrate-cathelicidin axis links dietary habits directly to intestinal antimicrobial defense and barrier function.

Frequently Asked Questions

Does LL-37 protect the gut barrier?

LL-37 protects the intestinal barrier through multiple mechanisms: direct killing of pathogenic bacteria at the mucosal surface, reorganization of tight junction proteins (especially ZO-1) in infected epithelium, enhanced mucin gene expression (MUC1, MUC2, MUC3), and promotion of epithelial wound healing. However, at higher concentrations in healthy tissue, LL-37 can transiently increase epithelial permeability by causing endocytosis of occludin and claudin-2.

How does butyrate increase LL-37 in the gut?

Butyrate, a short-chain fatty acid produced by gut bacteria fermenting dietary fiber, directly upregulates cathelicidin gene expression in colonic epithelial cells. This creates a diet-dependent defense system: high-fiber diets produce more butyrate, which increases LL-37 production, which enhances antimicrobial defense at the intestinal surface. Low-fiber diets reduce this entire cascade.

Is LL-37 altered in inflammatory bowel disease?

Yes, but differently depending on disease type. In Crohn's disease, reduced LL-37 expression in ileal mucosa has been reported, potentially contributing to impaired antimicrobial defense against adherent-invasive E. coli. In ulcerative colitis, some studies show increased LL-37 in inflamed colonic tissue, possibly as a compensatory defense response. The relationship between LL-37 and IBD appears bidirectional.

Does LL-37 affect tight junctions?

LL-37 has dual effects on tight junctions depending on context. In Salmonella-infected intestinal epithelial cells, LL-37 restored barrier integrity by reorganizing ZO-1 tight junction proteins. In healthy, uninfected cells, LL-37 caused transient permeability increases through endocytosis and degradation of occludin and claudin-2. This context-dependent behavior may serve immune surveillance purposes.

Where in the GI tract is LL-37 produced?

LL-37 is expressed by epithelial cells throughout the gastrointestinal tract, including the stomach, small intestine, and colon. Gastric epithelial cells produce LL-37 particularly in areas of H. pylori infection. Colonic expression is constitutive but modulated by short-chain fatty acids from gut bacteria, especially butyrate. Expression levels vary by region and are influenced by the local microbial environment.

How does LL-37 compare to BPC-157 for gut protection?

LL-37 and BPC-157 protect the gut through different mechanisms. LL-37 works at the barrier surface through direct antimicrobial killing, tight junction modulation, and mucus enhancement. BPC-157 may enhance angiogenesis and growth factor expression in the gut wall. LL-37 is an endogenous human peptide with well-characterized expression and regulation. BPC-157 is a synthetic gastric pentadecapeptide with primarily preclinical evidence. The two target different and complementary aspects of gut barrier biology and may have additive benefits.